New dosage and updated label for rare disease drug

Italian drugmaker Recordati (RECI: MI) has announced the US launch of a 350mg single-vial dosage strength of Panhematin (hemin for injection) for the amelioration of recurrent attacks of acute intermittent porphyria (AIP).

The new dosage strength of Panhematin – a product originally approved by the US Food and Drug Administration (FDA) in 1983 – is considered to more accurately reflect the dose required to treat most patients with AIP, and increases the number of people potentially eligible for treatment with only one vial per day.

AIP is a genetic metabolic disorder that affects the production of heme, a substance inside red blood cells that produces hemoglobin.